A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA(A)-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

BACKGROUND: There are currently no pharmacological therapies to address the intellectual disability associated with Down syndrome. Excitatory/inhibitory imbalance has been hypothesized to contribute to impairments in cognitive functioning in Down syndrome. Negative modulation of the GABA(A)-α5 recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Goeldner, Celia, Kishnani, Priya S., Skotko, Brian G., Casero, Julian Lirio, Hipp, Joerg F., Derks, Michael, Hernandez, Maria-Clemencia, Khwaja, Omar, Lennon-Chrimes, Sian, Noeldeke, Jana, Pellicer, Sabine, Squassante, Lisa, Visootsak, Jeannie, Wandel, Christoph, Fontoura, Paulo, d’Ardhuy, Xavier Liogier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903644/
https://www.ncbi.nlm.nih.gov/pubmed/35123401
http://dx.doi.org/10.1186/s11689-022-09418-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903644/
https://www.ncbi.nlm.nih.gov/pubmed/35123401
http://dx.doi.org/10.1186/s11689-022-09418-0

Ejemplares similares